Drug Information

Drug General Information
Drug ID
D0A9IY
Former ID
DIB001547
Drug Name
PF-4447943
Synonyms
PF-04447943; PDE9A inhibitor (AD), Pfizer; Phosphodiesterase 9A inhibitor (Alzheimer's disease), Pfizer
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2 [522709]
Company
Pfizer Inc
Structure
Download
2D MOL

3D MOL
Formula
C20H25N7O2
Canonical SMILES
C[C@@H]1CN(Cc2ncccn2)C[C@H]1C3=Nc4c(cnn4C5CCOCC5)C(=O)N<br />3
InChI
1S/C20H25N7O2/c1-13-10-26(12-17-21-5-2-6-22-17)11-16(13)18-24-19-15(20(28)25-18)9-23-27(19)14-3-7-29-8-4-14/h2,5-6,9,13-14,16H,3-4,7-8,10-12H2,1H3,(H,24,25,28)/t13-,16-/m1/s1
InChIKey
IWXUVYOOUMLUTQ-CZUORRHYSA-N
PubChem Compound ID
25115162
Target and Pathway
Target(s) Phosphodiesterase (PDE) 9 Target Info Inhibitor [532766]
KEGG Pathway Purine metabolism
Pathway Interaction Database Regulation of Androgen receptor activity
Reactome cGMP effects
References
Ref 522709ClinicalTrials.gov (NCT00930059) A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 532766A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.